Italfarmaco Spa patent expiration

1. Duvyzat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7329689 ITALFARMACO SPA Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
Jan, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421184 ITALFARMACO SPA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Feb, 2032

(7 years from now)

US9867799 ITALFARMACO SPA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Feb, 2032

(7 years from now)

US10688047 ITALFARMACO SPA Physically and chemically stable oral suspensions of givinostat
Oct, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2029
Orphan Drug Exclusivity(ODE-473) Mar 21, 2031

Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient

NCE-1 date: 21 March, 2028

Market Authorisation Date: 21 March, 2024

Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat

Dosage: SUSPENSION

More Information on Dosage

DUVYZAT family patents

Family Patents